Mistletoe

Metadata

Approved Indications

Commission E (Germany)

• Commission E published a negative monograph for Viscum album as a phytotherapeutic agent (i.e., did not approve it for conventional phytotherapy)
• However, this does not affect its status as an anthroposophic medicine, which operates under a separate regulatory pathway in Germany

ESCOP

• No ESCOP monograph for oncological use

EMA/HMPC

• Public statement (not a monograph): The HMPC concluded that oncological use falls outside the scope of the Directive 2001/83/EC for traditional herbal medicinal products
• Well-established use evaluation was considered “not yet possible” because essential criteria for evaluation are not fulfilled
• Effectively: no EMA herbal monograph exists for mistletoe

Anthroposophic Medicine Regulatory Pathway (Germany, Switzerland, Austria)

• Mistletoe preparations are licensed medicines under anthroposophic medicine regulations
• Partly reimbursable through the German, Swiss, and Austrian healthcare systems
• Licensed for adjunctive treatment in cancer (palliative care and quality of life improvement)
• This represents a unique regulatory pathway that does not exist in most other countries

Agreement/Disagreement Analysis

There is fundamental disagreement at every level:

• Commission E: negative monograph (as phytomedicine)
• EMA: cannot evaluate under existing framework
• German anthroposophic medicine law: approved and reimbursable
• US FDA: not approved for any indication; import prohibited except for research
• NCI/PDQ: acknowledges some evidence but does not recommend

Historical and Philosophical Context

Anthroposophic Medicine Origins

• Developed in the 1920s by Rudolf Steiner (1861-1925) and physician Ita Wegman (1876-1943)
• Steiner conjectured that mistletoe could treat cancer based on the observation that it is a parasite that eventually kills its host tree — a process he saw as analogous to cancer
• Steiner also believed the plant’s medical potential was influenced by celestial positioning (sun, moon, planets) and that harvest timing was important
• First patients treated with mistletoe extract circa 1920

Current Practice Context

• Anthroposophic medicine is recognized as a complementary medical system in Germany (special legal status since 1976 Arzneimittelgesetz)
• Mistletoe therapy is among the most prescribed complementary cancer treatments in German-speaking countries
• Up to 77% of oncological patients in German-speaking countries use mistletoe preparations
• Annual market exceeds EUR 30 million in Germany alone

Conditions Treated

Primary Use

• Cancer adjunctive therapy: Improvement of quality of life, reduction of treatment-related side effects, and claimed survival benefits in various cancer types

Specific Cancer Types Studied

• Breast cancer (most extensively studied)
• Colorectal cancer
• Pancreatic cancer
• Lung cancer
• Melanoma
• Bladder cancer
• Gynecological cancers

Secondary/Traditional Uses (historical)

• Hypertension (historical use, not current practice)
• Epilepsy (historical/folk medicine only)
• Arthritic joint pain (folk medicine)

Mechanism of Action

Key Active Compounds

Mistletoe Lectins (ML-I, ML-II, ML-III)

• Ribosome-inactivating proteins (Type II) sharing structural homology with ricin
• ML-I is considered the most pharmacologically important
• Mechanisms:
  • Direct cytotoxicity: inhibit protein synthesis in cancer cells
  • Induction of apoptosis (programmed cell death) in cancer cells
  • Immunomodulation: stimulate cytokine release (TNF-alpha, IL-1, IL-6)
  • Activate NK cells and macrophages
  • Increase white blood cell counts

Viscotoxins

• Small cytotoxic proteins (46 amino acids)
• Four major viscotoxins identified
• Direct cytotoxic effects on cancer cell membranes
• Membrane-disrupting activity

Immunogenic Cell Death (ICD) — Recent Discovery

• Mistletoe extracts trigger endoplasmic reticulum stress in cancer cells
• Leads to calreticulin exposure on cell surface (18-51% of cancer cells)
• Causes 7-fold increase in ATP release
• This ICD mechanism represents a paradigm shift: rather than just killing cancer cells, mistletoe may “teach” the immune system to recognize and attack them
• [NEEDS-RESEARCH] Clinical significance of ICD mechanism still being evaluated

Host Tree Dependency

• Composition of lectins and viscotoxins varies significantly depending on the host tree species
• Products are differentiated by host tree: apple (M), pine (P), oak (Qu), elm (U), ash, etc.
• Anthroposophic prescribing takes host tree into account (tumor type-specific recommendations)

Clinical Evidence Summary

Quality of Life Studies

• Multiple controlled studies show improvements in quality of life measures
• A systematic review by Kienle & Kiene (2010) of controlled clinical studies found that most studies reported QoL improvements
• Most consistent finding across the literature
• Improvements in fatigue, sleep, appetite, emotional wellbeing, and pain

Survival Studies

• Systematic literature review identified 49 publications on Iscador and survival
• Among 41 studies providing extractable hazard ratios, the majority reported positive effects favoring Iscador
• However: Most of these studies were non-randomized or had significant methodological limitations
• Prospective nonrandomized and randomized matched-pair studies nested within a cohort study showed survival benefits (Grossarth-Maticek et al.)

Methodological Criticisms

• Most clinical research is published in Germany by researchers with anthroposophic affiliations
• Ernst (2006 and subsequent reviews) concluded that research by anthroposophic clinicians often reached positive conclusions because it drew on unreliable material
• Independent researchers tended to find no evidence of benefit
• Heterogeneity problems: Different study populations, preparations, dosages, host trees, administration routes, and endpoints make meta-analysis difficult
• No transparent, standardized prescribing protocol exists across studies
• Blinding is difficult (injection site reactions are distinctive)
• The Cochrane review was unable to draw firm conclusions

Immunological Evidence

• More consistent evidence for immunomodulatory effects:
  • Increased NK cell activity
  • Increased lymphocyte counts
  • Enhanced cytokine profiles
  • Protection of leukocyte DNA from chemotherapy damage (in vitro)

The EU-US Divergence (Major Section)

European Position

US Position

• FDA has not approved mistletoe for any medical purpose
• Import and distribution prohibited for injectable mistletoe preparations (including homeopathic formulations), except for clinical research purposes
• FDA’s stated reason: commercial preparations contain multiple ingredients, making standardization of batches difficult
• NCI/PDQ acknowledges the evidence base but does not recommend clinical use
• Some clinical trials ongoing in the US (e.g., Johns Hopkins)
• Available through limited practitioner channels (oral/non-injectable forms less regulated)

Why the Divergence Exists

1. Regulatory framework: Germany has a specific legal pathway for anthroposophic medicines that does not require conventional RCT-based approval
2. Cultural integration: Anthroposophic medicine is deeply embedded in German healthcare culture since 1976
3. Evidence standards: German regulatory bodies accept a broader evidence base (including observational data and practitioner experience) for anthroposophic medicines
4. Philosophical differences: The anthroposophic model of cancer treatment (addressing the “whole person”) does not translate easily into the RCT paradigm
5. Economic factors: Significant market and infrastructure investments in German-speaking countries

Safety Profile

Contraindications

• Allergy to mistletoe proteins
• Active tuberculosis (theoretical immune stimulation concern)
• Hyperthyroidism (some preparations contain substances affecting thyroid)
• Protein hypersensitivity
• Use with caution in autoimmune conditions (immune stimulation may exacerbate)

Drug Interactions

• Immunosuppressants: Theoretical antagonism (mistletoe stimulates immune function)
• Chemotherapy agents: Interactions theoretically possible but not well-characterized; some practitioners use mistletoe concurrently with conventional chemotherapy
• Cardiac glycosides: Some mistletoe components may have cardiac effects

Side Effects

• Very common: Local injection site reactions (redness, swelling, warmth) — considered a therapeutic response in anthroposophic practice
• Common: Mild fever (also considered therapeutic); flu-like symptoms
• Uncommon: Headache, chills, fatigue
• Rare: Allergic reactions; anaphylaxis (very rare)
• Generally described as “well-tolerated” in clinical studies
• Intravenous administration had ~2x lower ADR rate compared to subcutaneous

Pregnancy/Lactation

• Contraindicated during pregnancy (uterotonic properties of viscotoxins)
• Insufficient data for lactation

Clinical Dosage

Administration

• Route: Predominantly subcutaneous injection (also: intravenous, intratumoral in selected cases)
• Frequency: 2-3 times per week
• Dose escalation: Start low, gradually increase based on local reaction, general condition, and body temperature regulation

Key Products and Dose Ranges

Note: Dose ranges differ dramatically between products because they are manufactured differently and standardized to different parameters. Direct dose comparison between products is not meaningful.

Host Tree Variants

• Iscador M (apple tree) — most commonly used
• Iscador P (pine tree)
• Iscador Qu (oak tree)
• Iscador U (elm tree)
• Selection guided by tumor type in anthroposophic prescribing

Sources

• NCI/PDQ: Mistletoe Extracts (PDQ) — Health Professional Version (cancer.gov)
• EMA/HMPC/196894/2012: Public Statement on Viscum album L., herba
• Grossarth-Maticek et al. (2001) “Use of Iscador, an extract of European mistletoe” PMID: 11347286
• Ernst (2006) and subsequent critical reviews of mistletoe evidence
• Kienle & Kiene (2010) “Influence of Viscum album L Extracts on Quality of Life in Cancer Patients” SAGE Journals
• Steele et al. (2014) “Safety of Intravenous Application of Mistletoe Preparations in Oncology” PMC4052504
• Memorial Sloan Kettering Cancer Center: Mistletoe (European) monograph
• CAM-Cancer: Mistletoe (Viscum album) summary
• OncoLink (Penn Medicine): Mistletoe monograph
• Medsektion Goetheanum: Cancer disease, mistletoe treatment

Connections

• Anthroposophic medicine module (if exists): Mistletoe is the flagship remedy of anthroposophic oncology
• Cancer-related herbs: Contrast with conventional phytotherapy approaches to cancer supportive care
• Immunomodulatory herbs: Compare mechanisms with echinacea, astragalus
• Regulatory frameworks module: The German anthroposophic medicine exemption (AMG 1976) is critical context